The U.S. dietary supplement industry continues to experience rapid growth, but 2026 has also become one of the most significant years for regulatory change in recent memory.
From FDA discussions on modernizing dietary ingredient regulations to new Customs and Border Protection (CBP) enforcement initiatives, manufacturers, importers, and dietary supplement brands are facing a more complex compliance landscape.
For ingredient suppliers, contract manufacturers, and supplement brands, understanding these regulatory developments is no longer optional—it is essential for maintaining market access and supply chain stability.
This article highlights the most important regulatory alerts currently affecting the U.S. dietary supplement market and what businesses should do to prepare.
In March 2026, the FDA announced a public meeting focused on dietary supplement innovation and the scope of dietary ingredients. This marks one of the most important regulatory discussions in years [From: FDA Public Meeting Announcement, March 2026].
The key question being debated is:
What types of substances should legally qualify as dietary ingredients under DSHEA?
The discussion is particularly relevant for emerging categories such as:
Industry groups have argued that the current framework, largely established in 1994, does not adequately address today's ingredient innovations. At the same time, consumer advocacy organizations are urging FDA to maintain strict safety standards before expanding ingredient eligibility.
Companies developing novel ingredients should expect:
For ingredient suppliers, regulatory documentation may become just as important as product quality.
Recent updates to the FDA NDI database reveal a continuing trend: Many NDI submissions are being challenged due to insufficient identity data or inadequate safety evidence [From: FDA NDI Notifications, 2026].
Industry observers report that less than half of recent submissions received favorable outcomes.
Common deficiencies include:
Some submissions were rejected because FDA questioned whether the substance met the legal definition of a dietary ingredient.
Companies planning to commercialize innovative ingredients should begin regulatory planning much earlier than before. The days of launching a novel ingredient first and addressing regulatory concerns later are rapidly disappearing.
Peptides continue to generate enormous market interest. Products such as:
have gained significant attention within the wellness and biohacking communities.
However, FDA's position remains largely unchanged: many peptides are viewed as drug-related substances rather than dietary ingredients [From: FDA Warning Letters, 2025-2026].
Industry stakeholders are actively pushing FDA to modernize its interpretation of dietary ingredient eligibility, but no major policy shift has occurred yet.
Companies should exercise caution when:
Products positioned too closely to pharmaceutical applications remain at elevated enforcement risk.
Recent FDA warning letters indicate that enforcement remains active in several areas [From: FDA Warning Letter Archive, 2026]:
Examples include claims suggesting treatment of:
Even when the ingredient itself is legal, inappropriate marketing claims can transform a dietary supplement into an unapproved drug in FDA's view.
Marketing compliance should receive the same attention as manufacturing compliance. Many enforcement actions originate from website claims rather than product quality issues.
Perhaps the most significant regulatory development of 2026 is not coming from FDA—it is coming from U.S. Customs and Border Protection (CBP). On June 3, 2026, the White House issued a new Executive Order directing comprehensive customs reform [From: White House Press Release, June 3, 2026].
The initiative is expected to dramatically increase scrutiny of Importers of Record (IORs).
Importers may be required to maintain higher customs bonds.
Importers could be required to demonstrate meaningful U.S.-based assets.
CBP plans to expand vetting procedures for:
Importers with compliance concerns may face restrictions on future import activities.
Many dietary supplement companies rely on:
These structures may face increased scrutiny under the new framework.
Companies should evaluate:
Businesses with strong U.S. operational presence are likely to face fewer disruptions than those relying on minimal U.S. infrastructure.
Regulators are increasingly requesting deeper supply chain visibility [From : CBP and Industry Reports, 2026].
Importers should expect growing demands for documentation regarding:
This trend aligns with broader enforcement efforts targeting:
For dietary ingredient suppliers, documentation quality is becoming a competitive advantage.
Despite increased regulatory attention, the U.S. dietary supplement market remains highly attractive.
Several trends continue driving demand:
Ingredients supporting longevity, cognition, and mitochondrial health remain strong growth categories.
Demand continues for:
Consumers increasingly seek products supporting:
Brands continue exploring customized formulations and condition-specific supplementation.
However, regulatory expectations are rising alongside market growth. The companies most likely to succeed will be those that combine:
The regulatory environment for dietary supplements is evolving rapidly.
In 2026, businesses must pay attention not only to FDA requirements but also to customs enforcement, import compliance, ingredient classification, and supply chain transparency.
For ingredient suppliers and supplement manufacturers, compliance is no longer merely a defensive strategy—it is becoming a competitive advantage. Companies that proactively strengthen their regulatory foundation today will be better positioned to serve the U.S. market tomorrow.
